Why an FDA decision on Stealth’s Barth drug could ripple through the rare disease field
Written by
BioPharma Dive
Published
0
comments
0
min
Stealth secured a new agency review of its experimental therapy elamipretide after a rejection this year. The result could carry broader consequences.